CA2291260A1 - 207 proteines secretees par l'etre humain - Google Patents
207 proteines secretees par l'etre humain Download PDFInfo
- Publication number
- CA2291260A1 CA2291260A1 CA002291260A CA2291260A CA2291260A1 CA 2291260 A1 CA2291260 A1 CA 2291260A1 CA 002291260 A CA002291260 A CA 002291260A CA 2291260 A CA2291260 A CA 2291260A CA 2291260 A1 CA2291260 A1 CA 2291260A1
- Authority
- CA
- Canada
- Prior art keywords
- gene
- tissues
- polypeptides
- seq
- useful
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 674
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 169
- 241000282414 Homo sapiens Species 0.000 title abstract description 38
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 14
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 12
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 12
- 239000013598 vector Substances 0.000 claims abstract description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 496
- 229920001184 polypeptide Polymers 0.000 claims description 493
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 493
- 230000014509 gene expression Effects 0.000 claims description 318
- 108091033319 polynucleotide Proteins 0.000 claims description 257
- 102000040430 polynucleotide Human genes 0.000 claims description 257
- 239000002157 polynucleotide Substances 0.000 claims description 256
- 239000012472 biological sample Substances 0.000 claims description 99
- 239000012634 fragment Substances 0.000 claims description 94
- 239000000047 product Substances 0.000 claims description 56
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 33
- 230000000694 effects Effects 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 239000002299 complementary DNA Substances 0.000 claims description 13
- 125000003729 nucleotide group Chemical group 0.000 claims description 12
- 239000002773 nucleotide Substances 0.000 claims description 11
- 230000027455 binding Effects 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000004166 bioassay Methods 0.000 claims description 3
- 230000004071 biological effect Effects 0.000 claims description 3
- 230000001575 pathological effect Effects 0.000 claims 8
- 230000037430 deletion Effects 0.000 claims 3
- 238000012217 deletion Methods 0.000 claims 3
- 239000006228 supernatant Substances 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract description 4
- 238000002405 diagnostic procedure Methods 0.000 abstract description 3
- 238000010188 recombinant method Methods 0.000 abstract description 2
- 108091026890 Coding region Proteins 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 817
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 484
- 210000004027 cell Anatomy 0.000 description 420
- 208000035475 disorder Diseases 0.000 description 366
- 239000000523 sample Substances 0.000 description 196
- 210000001124 body fluid Anatomy 0.000 description 195
- 235000018102 proteins Nutrition 0.000 description 158
- 238000003745 diagnosis Methods 0.000 description 152
- 201000010099 disease Diseases 0.000 description 118
- 239000003153 chemical reaction reagent Substances 0.000 description 102
- 210000002966 serum Anatomy 0.000 description 100
- 239000012530 fluid Substances 0.000 description 99
- 238000011282 treatment Methods 0.000 description 99
- 210000002381 plasma Anatomy 0.000 description 98
- 210000002700 urine Anatomy 0.000 description 98
- 210000001179 synovial fluid Anatomy 0.000 description 97
- 238000009826 distribution Methods 0.000 description 95
- 230000001900 immune effect Effects 0.000 description 95
- 206010028980 Neoplasm Diseases 0.000 description 61
- 210000000987 immune system Anatomy 0.000 description 46
- 208000026278 immune system disease Diseases 0.000 description 46
- 210000004556 brain Anatomy 0.000 description 41
- 238000001514 detection method Methods 0.000 description 34
- 210000000349 chromosome Anatomy 0.000 description 30
- 230000001605 fetal effect Effects 0.000 description 29
- 238000013519 translation Methods 0.000 description 28
- 210000001744 T-lymphocyte Anatomy 0.000 description 27
- 230000001850 reproductive effect Effects 0.000 description 22
- 210000000440 neutrophil Anatomy 0.000 description 21
- 201000011510 cancer Diseases 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 18
- 201000000980 schizophrenia Diseases 0.000 description 18
- 210000004185 liver Anatomy 0.000 description 17
- 239000003550 marker Substances 0.000 description 16
- 230000004770 neurodegeneration Effects 0.000 description 15
- 208000015122 neurodegenerative disease Diseases 0.000 description 15
- 210000003169 central nervous system Anatomy 0.000 description 14
- 208000024827 Alzheimer disease Diseases 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 13
- 206010012289 Dementia Diseases 0.000 description 13
- 206010026749 Mania Diseases 0.000 description 13
- 208000018737 Parkinson disease Diseases 0.000 description 13
- 210000000481 breast Anatomy 0.000 description 13
- 210000001072 colon Anatomy 0.000 description 13
- 210000002307 prostate Anatomy 0.000 description 13
- 206010033864 Paranoia Diseases 0.000 description 12
- 208000027099 Paranoid disease Diseases 0.000 description 12
- 230000003542 behavioural effect Effects 0.000 description 12
- 210000003734 kidney Anatomy 0.000 description 12
- 208000032839 leukemia Diseases 0.000 description 12
- 210000001550 testis Anatomy 0.000 description 12
- 206010061218 Inflammation Diseases 0.000 description 11
- 210000003754 fetus Anatomy 0.000 description 11
- 230000002757 inflammatory effect Effects 0.000 description 11
- 230000004054 inflammatory process Effects 0.000 description 11
- 210000004072 lung Anatomy 0.000 description 11
- 208000023105 Huntington disease Diseases 0.000 description 10
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 10
- 208000027866 inflammatory disease Diseases 0.000 description 10
- 210000001161 mammalian embryo Anatomy 0.000 description 10
- 210000000653 nervous system Anatomy 0.000 description 10
- 210000001672 ovary Anatomy 0.000 description 10
- 208000019906 panic disease Diseases 0.000 description 10
- 210000002826 placenta Anatomy 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 208000012902 Nervous system disease Diseases 0.000 description 9
- 208000025966 Neurological disease Diseases 0.000 description 9
- 210000000748 cardiovascular system Anatomy 0.000 description 9
- 230000007547 defect Effects 0.000 description 9
- 230000009547 development abnormality Effects 0.000 description 9
- 230000004069 differentiation Effects 0.000 description 9
- 210000002569 neuron Anatomy 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- 238000013456 study Methods 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 8
- 108010076504 Protein Sorting Signals Proteins 0.000 description 8
- 210000002889 endothelial cell Anatomy 0.000 description 8
- 239000003102 growth factor Substances 0.000 description 8
- 208000018706 hematopoietic system disease Diseases 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 208000017169 kidney disease Diseases 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 230000000926 neurological effect Effects 0.000 description 8
- 208000004235 neutropenia Diseases 0.000 description 8
- 230000019491 signal transduction Effects 0.000 description 8
- 208000024172 Cardiovascular disease Diseases 0.000 description 7
- 208000035473 Communicable disease Diseases 0.000 description 7
- 208000029462 Immunodeficiency disease Diseases 0.000 description 7
- 238000002512 chemotherapy Methods 0.000 description 7
- 210000001723 extracellular space Anatomy 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 208000019423 liver disease Diseases 0.000 description 7
- 210000002741 palatine tonsil Anatomy 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 210000000130 stem cell Anatomy 0.000 description 7
- 230000017423 tissue regeneration Effects 0.000 description 7
- 230000002792 vascular Effects 0.000 description 7
- 206010003246 arthritis Diseases 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 230000013020 embryo development Effects 0.000 description 6
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 210000003463 organelle Anatomy 0.000 description 6
- 210000004994 reproductive system Anatomy 0.000 description 6
- 208000030507 AIDS Diseases 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 5
- 208000012239 Developmental disease Diseases 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 210000001638 cerebellum Anatomy 0.000 description 5
- 230000004064 dysfunction Effects 0.000 description 5
- 230000002526 effect on cardiovascular system Effects 0.000 description 5
- 238000005755 formation reaction Methods 0.000 description 5
- 208000030159 metabolic disease Diseases 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- 210000004560 pineal gland Anatomy 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 208000003174 Brain Neoplasms Diseases 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 208000031229 Cardiomyopathies Diseases 0.000 description 4
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 4
- 208000017604 Hodgkin disease Diseases 0.000 description 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 4
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 4
- 206010061598 Immunodeficiency Diseases 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 208000000172 Medulloblastoma Diseases 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 102000015728 Mucins Human genes 0.000 description 4
- 108010063954 Mucins Proteins 0.000 description 4
- 101000931108 Mus musculus DNA (cytosine-5)-methyltransferase 1 Proteins 0.000 description 4
- 108050003452 SH2 domains Proteins 0.000 description 4
- 102000014400 SH2 domains Human genes 0.000 description 4
- 208000024313 Testicular Neoplasms Diseases 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 210000000133 brain stem Anatomy 0.000 description 4
- 230000028023 exocytosis Effects 0.000 description 4
- 210000002458 fetal heart Anatomy 0.000 description 4
- 230000003394 haemopoietic effect Effects 0.000 description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
- 208000006359 hepatoblastoma Diseases 0.000 description 4
- 230000007813 immunodeficiency Effects 0.000 description 4
- 239000003018 immunosuppressive agent Substances 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- 210000004995 male reproductive system Anatomy 0.000 description 4
- 210000002752 melanocyte Anatomy 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 4
- 230000035479 physiological effects, processes and functions Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 210000004739 secretory vesicle Anatomy 0.000 description 4
- 230000000946 synaptic effect Effects 0.000 description 4
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 241000972773 Aulopiformes Species 0.000 description 3
- 101710105206 C-Jun-amino-terminal kinase-interacting protein 1 Proteins 0.000 description 3
- 102100022291 C-Jun-amino-terminal kinase-interacting protein 1 Human genes 0.000 description 3
- 102000057710 Coatomer Human genes 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 101150064122 ISLR gene Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
- 206010042971 T-cell lymphoma Diseases 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 210000004727 amygdala Anatomy 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 210000005095 gastrointestinal system Anatomy 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 230000002489 hematologic effect Effects 0.000 description 3
- 210000000777 hematopoietic system Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000001817 pituitary effect Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 208000017497 prostate disease Diseases 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 108010005597 ran GTP Binding Protein Proteins 0.000 description 3
- 102000005912 ran GTP Binding Protein Human genes 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 208000037803 restenosis Diseases 0.000 description 3
- 210000001525 retina Anatomy 0.000 description 3
- 235000019515 salmon Nutrition 0.000 description 3
- 210000002536 stromal cell Anatomy 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- 108091006112 ATPases Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 2
- 208000020084 Bone disease Diseases 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 241000244203 Caenorhabditis elegans Species 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 101710135138 Coatomer subunit epsilon Proteins 0.000 description 2
- 102100036213 Collagen alpha-2(I) chain Human genes 0.000 description 2
- 101710126238 Collagen alpha-2(I) chain Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 2
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 2
- 101710146739 Enterotoxin Proteins 0.000 description 2
- 206010016952 Food poisoning Diseases 0.000 description 2
- 208000019331 Foodborne disease Diseases 0.000 description 2
- 102100029620 Immunoglobulin lambda constant 2 Human genes 0.000 description 2
- 108010004020 Immunoglobulin lambda-Chains Proteins 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 241000222740 Leishmania braziliensis Species 0.000 description 2
- 208000004554 Leishmaniasis Diseases 0.000 description 2
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 102000008730 Nestin Human genes 0.000 description 2
- 108010088225 Nestin Proteins 0.000 description 2
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108700022034 Opsonin Proteins Proteins 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 102000018546 Paxillin Human genes 0.000 description 2
- ACNHBCIZLNNLRS-UHFFFAOYSA-N Paxilline 1 Natural products N1C2=CC=CC=C2C2=C1C1(C)C3(C)CCC4OC(C(C)(O)C)C(=O)C=C4C3(O)CCC1C2 ACNHBCIZLNNLRS-UHFFFAOYSA-N 0.000 description 2
- 102100032572 Phospholipase A-2-activating protein Human genes 0.000 description 2
- 108090000944 RNA Helicases Proteins 0.000 description 2
- 102000004409 RNA Helicases Human genes 0.000 description 2
- 229940078123 Ras inhibitor Drugs 0.000 description 2
- 206010038997 Retroviral infections Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 102000005465 Stathmin Human genes 0.000 description 2
- 108050003387 Stathmin Proteins 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 2
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 2
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 2
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 2
- 206010057644 Testis cancer Diseases 0.000 description 2
- 108700031954 Tgfb1i1/Leupaxin/TGFB1I1 Proteins 0.000 description 2
- 102100033254 Tumor suppressor ARF Human genes 0.000 description 2
- 101710102803 Tumor suppressor ARF Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 206010047505 Visceral leishmaniasis Diseases 0.000 description 2
- 210000001766 X chromosome Anatomy 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 208000030270 breast disease Diseases 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 210000000750 endocrine system Anatomy 0.000 description 2
- 230000002357 endometrial effect Effects 0.000 description 2
- 239000000147 enterotoxin Substances 0.000 description 2
- 231100000655 enterotoxin Toxicity 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 210000003917 human chromosome Anatomy 0.000 description 2
- 208000003669 immune deficiency disease Diseases 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000000231 kidney cortex Anatomy 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 210000004901 leucine-rich repeat Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 229940051875 mucins Drugs 0.000 description 2
- 210000005055 nestin Anatomy 0.000 description 2
- 210000000933 neural crest Anatomy 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 102000044158 nucleic acid binding protein Human genes 0.000 description 2
- 108700020942 nucleic acid binding protein Proteins 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- ACNHBCIZLNNLRS-UBGQALKQSA-N paxilline Chemical compound N1C2=CC=CC=C2C2=C1[C@]1(C)[C@@]3(C)CC[C@@H]4O[C@H](C(C)(O)C)C(=O)C=C4[C@]3(O)CC[C@H]1C2 ACNHBCIZLNNLRS-UBGQALKQSA-N 0.000 description 2
- 108010044533 phospholipase A2-activating protein Proteins 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 210000005227 renal system Anatomy 0.000 description 2
- 208000017443 reproductive system disease Diseases 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 230000002381 testicular Effects 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 238000010798 ubiquitination Methods 0.000 description 2
- 230000034512 ubiquitination Effects 0.000 description 2
- 210000003606 umbilical vein Anatomy 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 101150038172 1.2 gene Proteins 0.000 description 1
- 101150072531 10 gene Proteins 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 101150098072 20 gene Proteins 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- 101150033839 4 gene Proteins 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 101150049308 54 gene Proteins 0.000 description 1
- 102100035916 60S ribosomal protein L11 Human genes 0.000 description 1
- 101150024653 61 gene Proteins 0.000 description 1
- 101150026651 63 gene Proteins 0.000 description 1
- 101150021183 65 gene Proteins 0.000 description 1
- 101150100400 66 gene Proteins 0.000 description 1
- 101150058202 73 gene Proteins 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 101150053844 APP1 gene Proteins 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 240000005528 Arctium lappa Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000036320 CAPN5-related vitreoretinopathy Diseases 0.000 description 1
- 101100228206 Caenorhabditis elegans gly-6 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102100035244 Cerebellin-1 Human genes 0.000 description 1
- 101710135505 Cerebellin-1 Proteins 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 102000005853 Clathrin Human genes 0.000 description 1
- 108010019874 Clathrin Proteins 0.000 description 1
- 102100028682 Claudin-11 Human genes 0.000 description 1
- 108050007280 Claudin-11 Proteins 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 108700022408 Coatomer Proteins 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 208000006992 Color Vision Defects Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 201000008163 Dentatorubral pallidoluysian atrophy Diseases 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 201000005231 Epithelioid sarcoma Diseases 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108010069271 FKBP-13 Proteins 0.000 description 1
- 241000714201 Feline calicivirus Species 0.000 description 1
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 1
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 1
- 108010058643 Fungal Proteins Proteins 0.000 description 1
- 101150061250 G9 gene Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000002966 Giant Cell Tumor of Bone Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101000977638 Homo sapiens Immunoglobulin superfamily containing leucine-rich repeat protein Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 101100189105 Homo sapiens PABPC4 gene Proteins 0.000 description 1
- 101000878215 Homo sapiens Peptidyl-prolyl cis-trans isomerase FKBP7 Proteins 0.000 description 1
- 101000574242 Homo sapiens RING-type E3 ubiquitin-protein ligase PPIL2 Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100023538 Immunoglobulin superfamily containing leucine-rich repeat protein Human genes 0.000 description 1
- 102100036340 Importin-5 Human genes 0.000 description 1
- 101710125769 Importin-5 Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 102000012411 Intermediate Filament Proteins Human genes 0.000 description 1
- 108010061998 Intermediate Filament Proteins Proteins 0.000 description 1
- 101710166851 JNK-interacting protein 1 Proteins 0.000 description 1
- 241000178949 Leishmania chagasi Species 0.000 description 1
- 241000222727 Leishmania donovani Species 0.000 description 1
- 241000222696 Leishmania guyanensis Species 0.000 description 1
- 241000222697 Leishmania infantum Species 0.000 description 1
- 241000222695 Leishmania panamensis Species 0.000 description 1
- 108700041567 MDR Genes Proteins 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- 206010057672 Male sexual dysfunction Diseases 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101100404023 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) arg-14 gene Proteins 0.000 description 1
- 102100023731 Noelin Human genes 0.000 description 1
- 101710157449 Noelin Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 208000016222 Pancreatic disease Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 1
- 102100026408 Peptidyl-prolyl cis-trans isomerase FKBP2 Human genes 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102100039424 Polyadenylate-binding protein 4 Human genes 0.000 description 1
- 208000033063 Progressive myoclonic epilepsy Diseases 0.000 description 1
- 101710136733 Proline-rich protein Proteins 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 102100025781 RING-type E3 ubiquitin-protein ligase PPIL2 Human genes 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 101100473039 Schistocerca americana HNRNP gene Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 101710082933 Single-strand DNA-binding protein Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 206010044002 Tonsil cancer Diseases 0.000 description 1
- 208000006842 Tonsillar Neoplasms Diseases 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 108010045245 alpha-latrotoxin receptor Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000010516 arginylation Effects 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000012012 beta Karyopherins Human genes 0.000 description 1
- 108010075890 beta Karyopherins Proteins 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 208000015606 cardiovascular system disease Diseases 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004656 cell transport Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000723 chemosensory effect Effects 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 229930193282 clathrin Natural products 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 201000007254 color blindness Diseases 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 108091007930 cytoplasmic receptors Proteins 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 208000023965 endometrium neoplasm Diseases 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 210000005153 frontal cortex Anatomy 0.000 description 1
- 230000006251 gamma-carboxylation Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 230000001456 gonadotroph Effects 0.000 description 1
- 150000003278 haem Chemical group 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000005096 hematological system Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229960000900 human factor viii Drugs 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000004305 hyperopia Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000008102 immune modulation Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 108010085650 interferon gamma receptor Proteins 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000003246 kidney medulla Anatomy 0.000 description 1
- 102000035110 latrophilin Human genes 0.000 description 1
- 108091005543 latrophilin Proteins 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000035168 lymphangiogenesis Effects 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000005063 microvascular endothelium Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 201000000626 mucocutaneous leishmaniasis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 230000025308 nuclear transport Effects 0.000 description 1
- 108010048477 olfactomedin Proteins 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 201000005737 orchitis Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 208000024691 pancreas disease Diseases 0.000 description 1
- 210000003695 paranasal sinus Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 244000000040 protozoan parasite Species 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 210000000449 purkinje cell Anatomy 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 108010025552 ribosomal protein L11 Proteins 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 201000004822 varicocele Diseases 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
- 230000007502 viral entry Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4718—Cytokine-induced proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (147)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4902097P | 1997-06-06 | 1997-06-06 | |
| US4901997P | 1997-06-06 | 1997-06-06 | |
| US4897497P | 1997-06-06 | 1997-06-06 | |
| US4897097P | 1997-06-06 | 1997-06-06 | |
| US4896497P | 1997-06-06 | 1997-06-06 | |
| US4889897P | 1997-06-06 | 1997-06-06 | |
| US4888197P | 1997-06-06 | 1997-06-06 | |
| US4889397P | 1997-06-06 | 1997-06-06 | |
| US4889497P | 1997-06-06 | 1997-06-06 | |
| US4887597P | 1997-06-06 | 1997-06-06 | |
| US4937497P | 1997-06-06 | 1997-06-06 | |
| US4888297P | 1997-06-06 | 1997-06-06 | |
| US4896397P | 1997-06-06 | 1997-06-06 | |
| US4887797P | 1997-06-06 | 1997-06-06 | |
| US4890097P | 1997-06-06 | 1997-06-06 | |
| US4887697P | 1997-06-06 | 1997-06-06 | |
| US4889697P | 1997-06-06 | 1997-06-06 | |
| US4888097P | 1997-06-06 | 1997-06-06 | |
| US4889997P | 1997-06-06 | 1997-06-06 | |
| US4897297P | 1997-06-06 | 1997-06-06 | |
| US4887897P | 1997-06-06 | 1997-06-06 | |
| US4888497P | 1997-06-06 | 1997-06-06 | |
| US4890197P | 1997-06-06 | 1997-06-06 | |
| US4889597P | 1997-06-06 | 1997-06-06 | |
| US4891697P | 1997-06-06 | 1997-06-06 | |
| US4894997P | 1997-06-06 | 1997-06-06 | |
| US4937397P | 1997-06-06 | 1997-06-06 | |
| US4897197P | 1997-06-06 | 1997-06-06 | |
| US4891597P | 1997-06-06 | 1997-06-06 | |
| US4896297P | 1997-06-06 | 1997-06-06 | |
| US4888597P | 1997-06-06 | 1997-06-06 | |
| US4888397P | 1997-06-06 | 1997-06-06 | |
| US4889797P | 1997-06-06 | 1997-06-06 | |
| US4889297P | 1997-06-06 | 1997-06-06 | |
| US4891797P | 1997-06-06 | 1997-06-06 | |
| US4937597P | 1997-06-06 | 1997-06-06 | |
| US60/048,970 | 1997-06-06 | ||
| US60/048,881 | 1997-06-06 | ||
| US60/048,878 | 1997-06-06 | ||
| US60/048,894 | 1997-06-06 | ||
| US60/048,900 | 1997-06-06 | ||
| US60/048,883 | 1997-06-06 | ||
| US60/048,896 | 1997-06-06 | ||
| US60/048,892 | 1997-06-06 | ||
| US60/048,895 | 1997-06-06 | ||
| US60/049,373 | 1997-06-06 | ||
| US60/049,020 | 1997-06-06 | ||
| US60/048,916 | 1997-06-06 | ||
| US60/048,974 | 1997-06-06 | ||
| US60/048,885 | 1997-06-06 | ||
| US60/048,880 | 1997-06-06 | ||
| US60/048,899 | 1997-06-06 | ||
| US60/048,901 | 1997-06-06 | ||
| US60/048,884 | 1997-06-06 | ||
| US60/048,915 | 1997-06-06 | ||
| US60/048,893 | 1997-06-06 | ||
| US60/049,375 | 1997-06-06 | ||
| US60/048,962 | 1997-06-06 | ||
| US60/048,877 | 1997-06-06 | ||
| US60/049,374 | 1997-06-06 | ||
| US60/048,971 | 1997-06-06 | ||
| US60/048,882 | 1997-06-06 | ||
| US60/048,917 | 1997-06-06 | ||
| US60/049,019 | 1997-06-06 | ||
| US60/048,898 | 1997-06-06 | ||
| US60/048,875 | 1997-06-06 | ||
| US60/048,964 | 1997-06-06 | ||
| US60/048,876 | 1997-06-06 | ||
| US60/048,972 | 1997-06-06 | ||
| US60/048,897 | 1997-06-06 | ||
| US60/048,963 | 1997-06-06 | ||
| US60/048,949 | 1997-06-06 | ||
| US5766197P | 1997-09-05 | 1997-09-05 | |
| US5777497P | 1997-09-05 | 1997-09-05 | |
| US5777697P | 1997-09-05 | 1997-09-05 | |
| US5776097P | 1997-09-05 | 1997-09-05 | |
| US5758497P | 1997-09-05 | 1997-09-05 | |
| US5777097P | 1997-09-05 | 1997-09-05 | |
| US5777597P | 1997-09-05 | 1997-09-05 | |
| US5766697P | 1997-09-05 | 1997-09-05 | |
| US5762897P | 1997-09-05 | 1997-09-05 | |
| US5763497P | 1997-09-05 | 1997-09-05 | |
| US5776397P | 1997-09-05 | 1997-09-05 | |
| US5766297P | 1997-09-05 | 1997-09-05 | |
| US5764297P | 1997-09-05 | 1997-09-05 | |
| US5764597P | 1997-09-05 | 1997-09-05 | |
| US5776297P | 1997-09-05 | 1997-09-05 | |
| US5777197P | 1997-09-05 | 1997-09-05 | |
| US5776997P | 1997-09-05 | 1997-09-05 | |
| US5765197P | 1997-09-05 | 1997-09-05 | |
| US5766797P | 1997-09-05 | 1997-09-05 | |
| US5764997P | 1997-09-05 | 1997-09-05 | |
| US5764397P | 1997-09-05 | 1997-09-05 | |
| US5766897P | 1997-09-05 | 1997-09-05 | |
| US5777797P | 1997-09-05 | 1997-09-05 | |
| US5776197P | 1997-09-05 | 1997-09-05 | |
| US5764897P | 1997-09-05 | 1997-09-05 | |
| US5765497P | 1997-09-05 | 1997-09-05 | |
| US5762997P | 1997-09-05 | 1997-09-05 | |
| US5764797P | 1997-09-05 | 1997-09-05 | |
| US5765097P | 1997-09-05 | 1997-09-05 | |
| US5776497P | 1997-09-05 | 1997-09-05 | |
| US5764697P | 1997-09-05 | 1997-09-05 | |
| US5776597P | 1997-09-05 | 1997-09-05 | |
| US5777897P | 1997-09-05 | 1997-09-05 | |
| US5762797P | 1997-09-05 | 1997-09-05 | |
| US5764497P | 1997-09-05 | 1997-09-05 | |
| US5763597P | 1997-09-05 | 1997-09-05 | |
| US60/057,769 | 1997-09-05 | ||
| US60/057,628 | 1997-09-05 | ||
| US60/057,654 | 1997-09-05 | ||
| US60/057,776 | 1997-09-05 | ||
| US60/057,666 | 1997-09-05 | ||
| US60/057,775 | 1997-09-05 | ||
| US60/057,649 | 1997-09-05 | ||
| US60/057,661 | 1997-09-05 | ||
| US60/057,777 | 1997-09-05 | ||
| US60/057,644 | 1997-09-05 | ||
| US60/057,647 | 1997-09-05 | ||
| US60/057,662 | 1997-09-05 | ||
| US60/057,761 | 1997-09-05 | ||
| US60/057,668 | 1997-09-05 | ||
| US60/057,635 | 1997-09-05 | ||
| US60/057,643 | 1997-09-05 | ||
| US60/057,645 | 1997-09-05 | ||
| US60/057,778 | 1997-09-05 | ||
| US60/057,760 | 1997-09-05 | ||
| US60/057,771 | 1997-09-05 | ||
| US60/057,667 | 1997-09-05 | ||
| US60/057,770 | 1997-09-05 | ||
| US60/057,763 | 1997-09-05 | ||
| US60/057,648 | 1997-09-05 | ||
| US60/057,642 | 1997-09-05 | ||
| US60/057,629 | 1997-09-05 | ||
| US60/057,646 | 1997-09-05 | ||
| US60/057,650 | 1997-09-05 | ||
| US60/057,774 | 1997-09-05 | ||
| US60/057,634 | 1997-09-05 | ||
| US60/057,627 | 1997-09-05 | ||
| US60/057,584 | 1997-09-05 | ||
| US60/057,651 | 1997-09-05 | ||
| US60/057,762 | 1997-09-05 | ||
| US60/057,764 | 1997-09-05 | ||
| US60/057,765 | 1997-09-05 | ||
| US7092397P | 1997-12-18 | 1997-12-18 | |
| US60/070,923 | 1997-12-19 | ||
| PCT/US1998/011422 WO1998054963A2 (fr) | 1997-06-06 | 1998-06-04 | 207 proteines secretees humaines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2291260A1 true CA2291260A1 (fr) | 1998-12-10 |
Family
ID=27587074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002291260A Abandoned CA2291260A1 (fr) | 1997-06-06 | 1998-06-04 | 207 proteines secretees par l'etre humain |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1039801A4 (fr) |
| CA (1) | CA2291260A1 (fr) |
| WO (1) | WO1998054963A2 (fr) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000047602A1 (fr) * | 1999-02-10 | 2000-08-17 | Human Genome Sciences, Inc. | 33 proteines humaines secretees |
| WO2001062891A2 (fr) * | 2000-02-24 | 2001-08-30 | Human Genome Sciences, Inc. | 207 proteines humaines secretees |
| EP0970209A1 (fr) * | 1997-03-28 | 2000-01-12 | Genetics Institute, Inc. | Proteines secretees et polynucleotides les codant |
| US6525174B1 (en) | 1997-06-06 | 2003-02-25 | Human Genome Sciences, Inc. | Precerebellin-like protein |
| EP1012261A4 (fr) * | 1997-08-06 | 2003-04-02 | Inst Genetics Llc | Proteines secretees et polynucleotides les codant |
| US7378507B2 (en) * | 1997-09-18 | 2008-05-27 | Genentech, Inc. | PRO217 polypeptides |
| US6075136A (en) * | 1998-02-17 | 2000-06-13 | Incyte Pharmaceuticals, Inc. | Prostate-associated serine protease |
| EP0939124A3 (fr) * | 1998-02-24 | 2001-03-21 | Smithkline Beecham Plc | Séquences de la MBGP1 |
| CA2321970A1 (fr) | 1998-02-26 | 1999-09-02 | Human Genome Sciences, Inc. | Proteines secretees par l'homme |
| CA2322711A1 (fr) * | 1998-02-27 | 1999-09-02 | Sagami Chemical Research Center | Proteines humaines possedant des domaines transmembranaires et adn codant ces proteines |
| AU3010199A (en) * | 1998-03-18 | 1999-10-11 | Icos Corporation | Human leupaxin polypeptide and dna encoding it, their uses |
| GB9807722D0 (en) * | 1998-04-08 | 1998-06-10 | Smithkline Beecham Plc | Novel compounds |
| DE19818619A1 (de) * | 1998-04-21 | 1999-10-28 | Metagen Gesellschaft Fuer Genomforschung Mbh | Menschliche Nukleinsäuresequenzen aus Blase-Tumor |
| WO2000037643A2 (fr) * | 1998-12-23 | 2000-06-29 | Corixa Corporation | Composes destines a l'immunotherapie et au diagnostic du cancer du colon et methodes d'utilisation |
| ES2315016T3 (es) | 1998-08-07 | 2009-03-16 | Immunex Corporation | Moleculas llamadas b7l-1. |
| WO2000012721A1 (fr) * | 1998-08-31 | 2000-03-09 | Long Yu | Nouveau gene de lysozyme humain, son polypeptide de codage et leur procede de preparation |
| AU2003204360B2 (en) * | 1998-09-01 | 2006-03-30 | Genentech, Inc. | Further pro polypeptides and sequences thereof |
| WO2000017354A1 (fr) * | 1998-09-18 | 2000-03-30 | Incyte Pharmaceuticals, Inc. | Proteine de liaison isre humaine |
| CA2344457A1 (fr) * | 1998-09-30 | 2000-04-06 | Millennium Pharmaceuticals, Inc. | Proteine et nouvelle molecule d'acide nucleique slgp et utilisations de celles-ci |
| US7414112B2 (en) | 1998-10-08 | 2008-08-19 | Genentech, Inc. | Antibodies to PRO1550 polypeptides |
| US6020164A (en) * | 1998-10-21 | 2000-02-01 | Incyte Pharmaceuticals, Inc. | Human RNA binding proteins |
| US6921658B1 (en) | 1998-11-20 | 2005-07-26 | Fuso Pharmacutical Industries, Ltd. | Serine protease BSSP6 |
| GB9828704D0 (en) * | 1998-12-24 | 1999-02-17 | Nippon Glaxo Limited | Proteins |
| US6387697B1 (en) | 1998-12-28 | 2002-05-14 | Corixa Corporation | Compositions for treatment and diagnosis of breast cancer and methods for their use |
| US6518237B1 (en) | 1998-12-28 | 2003-02-11 | Corixa Corporation | Compositions for treatment and diagnosis of breast cancer and methods for their use |
| US6586572B2 (en) | 1998-12-28 | 2003-07-01 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| US6969518B2 (en) | 1998-12-28 | 2005-11-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| US6573368B2 (en) | 1998-12-28 | 2003-06-03 | Corixa Corporation | Compositions for the treatment and diagnosis of breast cancer and methods for their use |
| US6844325B2 (en) | 1998-12-28 | 2005-01-18 | Corixa Corporation | Compositions for the treatment and diagnosis of breast cancer and methods for their use |
| US6579973B1 (en) | 1998-12-28 | 2003-06-17 | Corixa Corporation | Compositions for the treatment and diagnosis of breast cancer and methods for their use |
| US7598226B2 (en) | 1998-12-28 | 2009-10-06 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| US6680197B2 (en) | 1998-12-28 | 2004-01-20 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| US6528054B1 (en) | 1998-12-28 | 2003-03-04 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| US6958361B2 (en) | 1998-12-28 | 2005-10-25 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| US6590076B1 (en) | 1999-04-02 | 2003-07-08 | Corixa Corporation | Compositions for the treatment and diagnosis of breast cancer and methods for their use |
| EP1169332A4 (fr) * | 1999-03-12 | 2003-09-03 | Human Genome Sciences Inc | Proteines humaines secretees (49) |
| WO2000056753A1 (fr) * | 1999-03-23 | 2000-09-28 | Human Genome Sciences, Inc. | 49 proteines humaines secretees |
| EP1181390A4 (fr) * | 1999-03-18 | 2004-08-04 | Human Genome Sciences Inc | 27 proteines humaines secretees |
| JP2003501008A (ja) * | 1999-03-26 | 2003-01-14 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ５０個のヒト分泌タンパク質 |
| WO2000061743A1 (fr) | 1999-04-09 | 2000-10-19 | Shionogi & Co., Ltd. | Gene associe a l'apoptose |
| EP1177287A2 (fr) * | 1999-04-09 | 2002-02-06 | Chiron Corporation | Proteines humaines secretees |
| EP1181303A4 (fr) * | 1999-04-09 | 2003-04-09 | Human Genome Sciences Inc | 50 proteines humaines secretees |
| JP2002541850A (ja) * | 1999-04-15 | 2002-12-10 | オシリス セラピューティクス，インコーポレイテッド | 造血細胞からの遺伝子と発現産物 |
| KR20020011394A (ko) * | 1999-04-30 | 2002-02-08 | 미야타 도시오 | 메그-3 단백질 |
| NZ515132A (en) * | 1999-05-13 | 2005-01-28 | Johnson & Johnson Pharm Res | Sphingosine kinase enzyme |
| CA2374341A1 (fr) * | 1999-05-20 | 2000-11-30 | Takeda Chemical Industries, Ltd. | Nouveau polypeptide |
| EP1206573A4 (fr) * | 1999-06-07 | 2004-08-04 | Human Genome Sciences Inc | 26 proteines humaines secretees |
| EP1192176A4 (fr) * | 1999-06-11 | 2003-03-05 | Human Genome Sciences Inc | 49 proteines secretees humaines |
| AU5308200A (en) * | 1999-06-11 | 2001-01-02 | Human Genome Sciences, Inc. | 48 human secreted proteins |
| EP1192171A4 (fr) * | 1999-06-11 | 2003-05-07 | Human Genome Sciences Inc | 48 proteines secretees humaines |
| CA2382748A1 (fr) * | 1999-06-11 | 2000-12-21 | Human Genome Sciences, Inc. | 50 proteines humaines secretees |
| JP2004500032A (ja) * | 1999-07-14 | 2004-01-08 | インサイト・ゲノミックス・インコーポレイテッド | 電子輸送タンパク質 |
| WO2001009318A1 (fr) * | 1999-07-29 | 2001-02-08 | Helix Research Institute | Genes associes au cancer du foie |
| US6673570B1 (en) * | 1999-09-20 | 2004-01-06 | Ludwig Institute For Cancer Research | Smad associating polypeptides |
| WO2001021794A2 (fr) * | 1999-09-20 | 2001-03-29 | Ludwig Institute For Cancer Research | Polypeptides associant smad |
| JP2003517297A (ja) * | 1999-09-23 | 2003-05-27 | ライジェル・ファーマシューティカルズ・インコーポレイテッド | チェックポイント遺伝子関連細胞周期タンパク質、組成物および使用法 |
| JP2003512072A (ja) * | 1999-10-28 | 2003-04-02 | ワーナー−ランバート・カンパニー | ヒトスフィンゴシンキナーゼ遺伝子 |
| EP1248800A2 (fr) | 1999-11-30 | 2002-10-16 | Corixa Corporation | Compositions et methodes destinees au traitement et au diagnostic du cancer du sein |
| DK1246917T3 (da) | 2000-01-13 | 2009-06-08 | Genentech Inc | Humane Stra6-polypeptider |
| EP1257637A2 (fr) * | 2000-02-14 | 2002-11-20 | Curagen Corporation | Nouvelles kinases de sphingosine |
| EP1313503A4 (fr) * | 2000-07-24 | 2005-05-04 | Human Genome Sciences Inc | Recepteurs de facteur de necrose tumorale humains tr21 et tr22 |
| AU2002223568A1 (en) * | 2000-09-27 | 2002-04-08 | Vlaams Interuniversitair Instituut Voor Biotechnologie | Identification of neuroblastoma tumor suppressor genes |
| US6630325B1 (en) * | 2000-10-19 | 2003-10-07 | Maine Medical Center Research Institute | Compositions, methods and kits relating to remodel |
| AU2002229091A1 (en) * | 2001-06-20 | 2003-01-08 | Genentech, Inc. | Secreted polypeptide and their use in the treatment of bone disorders |
| WO2003025135A2 (fr) * | 2001-09-14 | 2003-03-27 | Gene Logic, Inc. | Genes associes a des tumeurs malignes |
| EP2305710A3 (fr) | 2002-06-03 | 2013-05-29 | Genentech, Inc. | Bibliothèques de phages et anticorps synthétiques |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996017925A1 (fr) * | 1994-12-06 | 1996-06-13 | Immunex Corporation | Cytokine designee par lerk-7 |
| CA2227220A1 (fr) * | 1995-07-19 | 1997-02-06 | Genetics Institute, Inc. | Proteines humaines ctla-8 et utilisation de proteines apparentees aux proteines ctla-8 |
-
1998
- 1998-06-04 EP EP98926237A patent/EP1039801A4/fr not_active Withdrawn
- 1998-06-04 WO PCT/US1998/011422 patent/WO1998054963A2/fr not_active Application Discontinuation
- 1998-06-04 CA CA002291260A patent/CA2291260A1/fr not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1039801A4 (fr) | 2003-03-26 |
| EP1039801A1 (fr) | 2000-10-04 |
| WO1998054963A2 (fr) | 1998-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2291260A1 (fr) | 207 proteines secretees par l'etre humain | |
| US20050089911A1 (en) | 87 human secreted proteins | |
| US20030055236A1 (en) | Secreted protein HKABT24 | |
| WO2000006698A1 (fr) | 98 proteines humaines secretees | |
| CA2295474A1 (fr) | 123 proteines humaines secretees | |
| CA2331154A1 (fr) | Polypeptides presentant une sequence distincte comprenant une sous-unite de facteur de croissance insulinomimetique labile en milieu acide | |
| US6525174B1 (en) | Precerebellin-like protein | |
| CA2332109A1 (fr) | 97 proteines humaines secretees | |
| CA2323761A1 (fr) | 95 proteines humaines secretees | |
| CA2319129A1 (fr) | 67 proteines humaines secretees | |
| EP1015477A1 (fr) | 32 proteines secretees par l'homme | |
| US6878687B1 (en) | Protein HMAAD57 | |
| WO1999024836A1 (fr) | 125 proteines secretees humaines | |
| CA2296815A1 (fr) | Serie de 64 proteines humaines secretees | |
| CA2322728A1 (fr) | 31 proteines humaines secretees | |
| CA2294705A1 (fr) | 19 proteines secretees par l'etre humain | |
| CA2305690A1 (fr) | 53 proteines secretees humaines | |
| EP1042674A1 (fr) | 148 proteines humaines secretees | |
| CA2298852A1 (fr) | 83 proteines humaines secretees | |
| CA2302387A1 (fr) | 29 proteines humaines secretees | |
| CA2305685A1 (fr) | 101 proteines humaines secretees | |
| US20070238664A1 (en) | 70 Human Secreted Proteins | |
| US20050214844A1 (en) | 86 human secreted proteins | |
| CA2383048A1 (fr) | 49 proteines humaines secretees | |
| EP1439189A2 (fr) | 86 protéines humainess sécrétées |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |